362 related articles for article (PubMed ID: 31189645)
1. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
[TBL] [Abstract][Full Text] [Related]
2. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
[TBL] [Abstract][Full Text] [Related]
3. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
4. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
5. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.
Martinez-Morilla S; Moutafi M; Fernandez AI; Jessel S; Divakar P; Wong PF; Garcia-Milian R; Schalper KA; Kluger HM; Rimm DL
Oncoimmunology; 2023; 12(1):2260618. PubMed ID: 37781235
[TBL] [Abstract][Full Text] [Related]
6. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.
Zugazagoitia J; Gupta S; Liu Y; Fuhrman K; Gettinger S; Herbst RS; Schalper KA; Rimm DL
Clin Cancer Res; 2020 Aug; 26(16):4360-4368. PubMed ID: 32253229
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
9. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.
Martinez-Morilla S; Villarroel-Espindola F; Wong PF; Toki MI; Aung TN; Pelekanou V; Bourke-Martin B; Schalper KA; Kluger HM; Rimm DL
Clin Cancer Res; 2021 Apr; 27(7):1987-1996. PubMed ID: 33504554
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.
Moutafi M; Martinez-Morilla S; Divakar P; Vathiotis I; Gavrielatou N; Aung TN; Yaghoobi V; Fernandez AI; Zugazagoitia J; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2022 Aug; 17(8):991-1001. PubMed ID: 35490853
[TBL] [Abstract][Full Text] [Related]
11. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.
Beechem JM
Methods Mol Biol; 2020; 2055():563-583. PubMed ID: 31502169
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
13. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
16. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
17. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.
Mezheyeuski A; Bergsland CH; Backman M; Djureinovic D; Sjöblom T; Bruun J; Micke P
J Pathol; 2018 Apr; 244(4):421-431. PubMed ID: 29282718
[TBL] [Abstract][Full Text] [Related]
18. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
Tumori; 2019 Dec; 105(6):465-473. PubMed ID: 31446882
[TBL] [Abstract][Full Text] [Related]
19. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
20. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
